ICU Medical(US:ICUI)2026-02-19 22:32Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $536 million, representing a 2% organic growth but a -14% reported decline, with full-year organic growth at 5% [4] - Gross margins were above 40%, with EBITDA of $98 million and EPS of $1.91, reflecting a year-over-year decline in EBITDA due to deconsolidation and tariffs [5][16] - Adjusted diluted EPS for Q4 was $1.91, down 9% from $2.11 the previous year [17] Business Line Data and Key Metrics Changes - Consumables business grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic [7][8] - IV systems business grew 3% reported and 1% organic, with LVPs showing low double-digit growth for the year [8][9] - Vital Care decreased 6% organically and 35% reported due to deconsolidation, remaining flat for the year [10] Market Data and Key Metrics Changes - The demand environment in Q4 was attractive across most geographies, with a notable flu spike in the U.S. towards year-end [6] - The capital environment remained stable, with investments being executed as planned [7] Company Strategy and Development Direction - The company aims to create a comprehensive infusion therapy company, focusing on operational stability and innovation [4][30] - Future growth is expected to be driven by volume increases in core infusion lines and niche markets, with a long-term goal of mid-single-digit growth [18][19] - The company is working on integrating manufacturing and IT systems to improve operational efficiency and profitability [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the capital environment and ongoing demand for their products [7][36] - The company anticipates improved free cash flow in 2026, driven by higher earnings and reduced spending on restructuring and integration [24][25] - Management acknowledged challenges from tariffs and interest rates but believes they can overcome these hurdles [27][32] Other Important Information - The company ended 2025 with $1.3 billion in debt and $308 million in cash, having paid down $303 million in principal during the year [18][25] - The company expects to reach a targeted leverage ratio of 2 times by early 2027, prioritizing debt repayment with free cash flow [25][26] Q&A Session Summary Question: Can you discuss the current customer environment for systems? - Management indicated that the capital environment has been stable, with deals being executed as expected [37] Question: What is the expected impact of new product clearances on sales? - Management stated that there has been no slowdown in sales due to pending clearances, and customers are engaged with future product roadmaps [41] Question: How is the company addressing tariff impacts? - Management confirmed ongoing structural changes to mitigate tariff impacts, with some benefits already seen in Q4 [52][53] Question: What is the market size and share for syringe pumps? - Management clarified that the syringe pump market is significantly smaller than LVPs, but they hold a higher market share in syringes [58][59] Question: What are the margins for the Vital Care business? - Management indicated that Vital Care likely operates below corporate gross margins, complicating potential divestiture discussions [63]